The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors

Allison, 1977, The role of de novo purine synthesis in lymphocyte transformation, Ciba Found. Symp., 48, 207

Allison, 2000, Mycophenolate mofetil and its mechanisms of action, Immunopharmacology, 47, 10.1016/S0162-3109(00)00188-0

Almquist, 1998, VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent

Amzel, 1998, Structure-based drug design, Curr. Opin. Biotechnol., 9, 366, 10.1016/S0958-1669(98)80009-8

Anderson, 1996, Synthesis and modeling studies with monocyclic analogues of mycophenolic acid, J. Med. Chem., 39, 46, 10.1021/jm9501339

Antonino, 1994, Probing the active site of human IMP dehydrogenase using halogenated purine riboside 5′-monophosphates and covalent modification reagents, Biochemistry, 33, 1760, 10.1021/bi00173a019

Bateman, 1997, The structure of a domain common to archaebacteria and the homocysteinuria disease protein, Trends Biochem. Sci., 22, 12, 10.1016/S0968-0004(96)30046-7

Balzarini, 1993, EICAR (5-ethynyl-1-β-d-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis, J. Biol. Chem., 268, 24591, 10.1016/S0021-9258(19)74507-4

Bemis, 1992, A fast and efficient method of 2D and 3D molecular shape description, J. Comput.-Aided Mol. Des., 6, 607, 10.1007/BF00126218

Berman, 1982, In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages, Antimicrob. Agents Chemother., 21, 887, 10.1128/AAC.21.6.887

Borel, 1991, The discovery and development of cyclosporine (Sandimmune), Transplant. Proc., 23, 1867

Bullingham, 1998, Clinical pharmacokinetics of mycophenolate mofetil, Clin. Pharmacokinet., 34, 429, 10.2165/00003088-199834060-00002

Carr, 1993, Characterization of human type I and type II IMP dehydrogenases, J. Biol. Chem., 268, 27286, 10.1016/S0021-9258(19)74247-1

Carson, 1991, Ribbons 2.0, J. Appl. Crystallogr., 24, 958, 10.1107/S0021889891007240

Carter, 1969, Mycophenolic acid: an anti-cancer compound with unusual properties, Nature, 223, 848, 10.1038/223848a0

Colby, 1999, Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design, Proc. Natl. Acad. Sci. U. S. A., 96, 3531, 10.1073/pnas.96.7.3531

Collart, 1988, Cloning and sequence analysis of the human and Chinese hamster inosine-5'-monophosphate dehydrogenase cDNAs, J. Biol. Chem., 263, 15769, 10.1016/S0021-9258(19)37654-9

Cooney, 1982, The conversion of 2-β-d-ribofuranosylthiazole-4-carboxamide to an analogue of NAD+ with potent IMP dehydrogenase-inhibitory properties, Biochem. Pharmacol., 31, 2133, 10.1016/0006-2952(82)90436-1

Davis, 1998, Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C, N. Engl. J. Med., 339, 1493, 10.1056/NEJM199811193392102

Decker, 1999, The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves GvHD in mouse, Transplantation, 67, S57, 10.1097/00007890-199904150-00232

Eugui, 1991, Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion, Scand. J. Immunol., 33, 161, 10.1111/j.1365-3083.1991.tb03746.x

Farazi, 1997, Isolation and characterization of mycophenolic acid-resistant mutants of inosine-5'-monophosphate dehydrogenase, J. Biol. Chem., 272, 961, 10.1074/jbc.272.2.961

Fleming, 1996, Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis, Biochemistry, 35, 6990, 10.1021/bi9607416

Franklin, 1969, The inhibition of nucleic acid synthesis by mycophenolic acid, Biochem. J., 113, 515, 10.1042/bj1130515

Franklin, 1994, Pharmacodynamics of the inhibition of GTP synthesis in vivo by mycophenolic acid, Adv. Enzyme Regul., 34, 107, 10.1016/0065-2571(94)90011-6

Franklin, 1997, Human colorectal carcinoma cells in vitro as a means to assess the metabolism of analogs of mycophenolic acid, Drug Metab. Dispos., 25, 367

Gosio, 1896, Richerche batteriologiche e chimiche sulle alterazioni del mais, Riv. Ig. Sanita Pubblica Ann., 7, 825

Gummert, 1999, The IMPDH inhibitor VX-497 is the first rationally synthesized immunosuppressant to prolong allograft survival, Transplantation, 67, S62, 10.1097/00007890-199904150-00249

Hedstrom, 1990, Mycophenolic acid and adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanism, Biochemistry, 29, 849, 10.1021/bi00456a001

Herrmann, 2000, Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases, Immunopharmacology, 47, 273, 10.1016/S0162-3109(00)00191-0

Holmes, 1974, Human IMP dehydrogenase. Kinetics and regulatory properties, Biochim. Biophys. Acta, 364, 209, 10.1016/0005-2744(74)90006-0

Huete-Pérez, 1995, Identification of the IMP binding site in the IMP dehydrogenase from Tritrichomonas foetus, Biochemistry, 34, 13889, 10.1021/bi00042a021

Hupe, 1986, IMP dehydrogenase from the intracellular parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid, J. Biol. Chem., 261, 8363, 10.1016/S0021-9258(19)83921-2

Jackson, 1975, IMP dehydrogenase, an enzyme linked with proliferation and malignancy, Nature, 256, 331, 10.1038/256331a0

Jarvis, 1973, Clustering using a similarity measure based on shared near neighbors, IEEE Trans. Comput., C-22, 1025, 10.1109/T-C.1973.223640

Keown, 1996, A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation, Transplantation, 61, 1029, 10.1097/00007890-199604150-00008

Kobashigawa, 1998, A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients, Transplantation, 66, 507, 10.1097/00007890-199808270-00016

Kornberg, 1992

Kuntz, 1982, A geometric approach to macromolecule-ligand interactions, J. Mol. Biol., 161, 269, 10.1016/0022-2836(82)90153-X

Kusumi, 1988, Dual inhibitory effect of bredinin, Cell Biochem. Funct., 7, 201, 10.1002/cbf.290070308

Kwong, 1999, VX-497, a novel IMPDH inhibitor, is a broad spectrum antiviral agent with superior activity compared to ribavirin against selected DNA and RNA viruses in vitro, vol. 18

Lesiak, 1998, Synthesis of a methylenebis (phosphonate) analogue of mycophenolic adenine dinucleotide: a glucuronidation-resistant MAD analogue of NAD, J. Med. Chem., 41, 618, 10.1021/jm970705k

Lightfoot, 1994, Gene amplification and dual point mutations of mouse IMP dehydrogenase associated with cellular resistance of mycophenolic acid, Biochem. Biophys. Acta, 1217, 156

Link, 1996, Trapping of an IMP dehydrogenase-substrate covalent intermediate by mycophenolic acid, J. Am. Chem. Soc., 118, 2091, 10.1021/ja9534056

Liu, 1993, FK506 and cyclosporin: molecular probes for studying intracellular signal transduction, Trends Pharmacol. Sci., 14, 182, 10.1016/0165-6147(93)90206-Y

Matsuda, 2000, Mechanisms of action of cyclosporine, Immunopharmacology, 47, 119, 10.1016/S0162-3109(00)00192-2

McHutchison, 1998, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, N. Engl. J. Med., 339, 1485, 10.1056/NEJM199811193392101

Mitsui, 1969, Immunosuppressive effect of mycophenolic acid, J. Antibiot., 22, 358, 10.7164/antibiotics.22.358

Mizuno, 1974, Studies on bredinin: I. Solation, characterization and biological properties, J. Antibiot., 27, 775, 10.7164/antibiotics.27.775

Morris, 1998, Inhibitors of the enzyme purine nucleoside phosphorylase, Expert Opin. Ther. Patents, 8, 283, 10.1517/13543776.8.3.283

Morris, 1996, Mechanisms of action of new immunosuppressive drugs, Kidney Int., 49, S26

Murcko, 1997, Recent advances in ligand design methods, 1, 10.1002/9780470125885.ch1

Natsumeda, 1993, Human type I and type II IMP dehydrogenases as drug targets, Ann. N. Y. Acad. Sci., 696, 88, 10.1111/j.1749-6632.1993.tb17144.x

Navia, 1996, Protein drug complexes important for immunoregulation and organ transplantation, Curr. Opin. Struct. Biol., 6, 838, 10.1016/S0959-440X(96)80015-7

Nelson, 1990, Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid, J. Med. Chem., 33, 833, 10.1021/jm00164a057

Nelson, 1996, Structure–activity relationships for inhibition of inosine monophosphate dehydrogenase by nuclear variants of mycophenolic acid, J. Med. Chem., 39, 4181, 10.1021/jm9603633

Neyts, 1996, Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections, Antiviral Res., 30, 125, 10.1016/0166-3542(96)89697-5

Nimmesgern, 1996, Conformational changes and stabilization of inosine 5′-monophosphate dehydrogenase associated with ligand binding and inhibition by mycophenolic acid, J. Biol. Chem., 271, 19421, 10.1074/jbc.271.32.19421

Nimmesgern, 2000, Biochemical analysis of the modular enzyme inosine 5′-monophosphate dehydrogenase, Protein Expression Purif., 17, 282, 10.1006/prep.1999.1136

Oliyaei, 1998, Pharmacology of immunosuppressive drugs, Drugs Today, 34, 463, 10.1358/dot.1998.34.5.485245

Pankiewicz, 1999, Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents, Expert Opin. Ther. Patents, 9, 55, 10.1517/13543776.9.1.55

Pichlmayr, 1995, Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection, Lancet, 345, 1321, 10.1016/S0140-6736(95)92534-1

Poynard, 1998, Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus, Lancet, 352, 1426, 10.1016/S0140-6736(98)07124-4

Schalk-Hihi, 1998, The conformation of NADH bound to inosine 5′-monophosphate dehydrogenase determined by transferred nuclear Overhauser effect spectroscopy, Biochemistry, 37, 7608, 10.1021/bi980214h

Schreiber, 1992, Immunophilin-sensitive protein phosphatase action in cell signaling pathways, Cell, 70, 365, 10.1016/0092-8674(92)90158-9

Sidwell, 1972, Broad-spectrum antiviral activity of virazole: 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide, Science, 177, 705, 10.1126/science.177.4050.705

Silverman Kitchin, 1997, Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses, J. Am. Acad. Dermatol., 37, 445, 10.1016/S0190-9622(97)70147-6

Sintchak, 1996, Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid, Cell, 85, 921, 10.1016/S0092-8674(00)81275-1

Sintchak, 1999, X-ray crystal structure of the antiviral drug ribavirin monophosphate bound to IMP dehydrogenase, vol. 76

Sollinger, 1995, Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients, Transplantation, 60, 225, 10.1097/00007890-199508000-00003

Spector, 1979, Reaction mechanism and specificity of human GMP reductase. Substrates, inhibitors, activators, and inactivators, J. Biol. Chem., 254, 2308, 10.1016/S0021-9258(17)30222-3

Streeter, 1973, Mechanism of action of 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent, Proc. Natl. Acad. Sci. U. S. A., 70, 1174, 10.1073/pnas.70.4.1174

Suthanthiran, 1996, Immunosuppressants: cellular and molecular mechanisms of action, Am. J. Kidney Dis., 28, 159, 10.1016/S0272-6386(96)90297-8

Tricot, 1989, Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity, Cancer Res., 49, 3696

Tricot, 1990, Tiazofurin. Biological effects and clinical uses, Int. J. Cell Cloning, 8, 161, 10.1002/stem.5530080303

Verham, 1987, Purification, characterization, and kinetic analysis of inosine 5′-monophosphate dehydrogenase of Tritrichomonas foetus, Mol. Biochem. Parasitol., 24, 1, 10.1016/0166-6851(87)90110-1

Wang, 1984, Differential effects of inhibitors of purine metabolism on two trichomonad species, Biochem. Pharmacol., 33, 1323, 10.1016/0006-2952(84)90187-4

Wang, 1996, Inactivation of inosine 5′-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-β-d-ribofuranosylimidazole-4-carboxamide 5′-monophosphate, Biochemistry, 35, 95, 10.1021/bi951499q

Wang, 1997, Kinetic mechanism of human inosine 5′-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products, Biochemistry, 36, 8479, 10.1021/bi970226n

Wang, 1998, A potent “fat base” nucleotide inhibitor of IMP dehydrogenase, Biochemistry, 37, 11949, 10.1021/bi981132w

Whitby, 1997, Crystal structure of Tritrichomonas foetus inosine-5′-monophosphate dehydrogenase and the enzyme-product complex, Biochemistry, 36, 10666, 10.1021/bi9708850

Williams, 1968, Mycophenolic acid: antiviral and antitumor properties, J. Antibiot., 21, 463, 10.7164/antibiotics.21.463

Xiang, 1996, Monovalent cation activation and kinetic mechanism of inosine 5′-monophosphate dehydrogenase, J. Biol. Chem., 271, 1435, 10.1074/jbc.271.3.1435

Zhang, 1999, Characteristics and crystal structure of bacterial inosine-5′-monophosphate dehydrogenase, Biochemistry, 38, 4691, 10.1021/bi982858v